Thanks for your input. The use of gemlapodect for Tourettes and stuttering may be totally different in the sense that it may work for one but not the other. I don't believe that a medication can "go to market" unless it passes a phase 3 trial and then receives FDA approval. If the Orpheus trial was promising I would think that Noema would've given a status update by now including intent for phase 3 testing.